Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor
作者:Claudia Contadini、Claudia Cirotti、Anna Carbone、Mehrdad Norouzi、Annarita Cianciusi、Emmanuele Crespan、Cecilia Perini、Giovanni Maga、Daniela Barilà、Francesca Musumeci、Silvia Schenone
DOI:10.3390/ph16070958
日期:——
including glioblastoma (GBM), has been extensively demonstrated. In this context, we started from our in-house library of pyrazolo[3,4-d]pyrimidines that are active as Src and/or Bcr-Abl TK inhibitors and performed a lead optimization study to discover a new generation derivative that is suitable for Src kinase targeting. We synthesized a library of 19 compounds, 2a-s. Among these, compound 2a (SI388)
Src 是一种非受体酪氨酸激酶 (TK),其与癌症(包括胶质母细胞瘤 (GBM))的参与已被广泛证明。在这种情况下,我们从具有 Src 和/或 Bcr-Abl TK 抑制剂活性的吡唑并[3,4-d]嘧啶的内部库开始,进行了先导化合物优化研究,以发现适合的新一代衍生物用于 Src 激酶靶向。我们合成了 19 种化合物(2a-s)的库。其中,化合物 2a (SI388) 被确定为最有效的 Src 抑制剂。基于无细胞结果,我们研究了 SI388 在 2D 和 3D GBM 细胞模型中的作用。有趣的是,SI388 显着抑制 Src 激酶,从而影响细胞活力、致瘤性并增强癌细胞对电离辐射的敏感性。